SaNOtize Research and Development Corp. Revenue and Competitors

Location

#7503

Growjo Ranking

Biotech

Industry

Estimated Revenue & Valuation

  • SaNOtize Research and Development Corp.'s estimated annual revenue is currently $2M per year.(i)
  • SaNOtize Research and Development Corp.'s estimated revenue per employee is $77,500

Employee Data

  • SaNOtize Research and Development Corp. has 26 Employees.(i)
  • SaNOtize Research and Development Corp. grew their employee count by 8% last year.

SaNOtize Research and Development Corp.'s People

NameTitleEmail/Phone
1
Chief Science Officer & Co-FounderReveal Email/Phone
2
Co founder, Chief Strategy and Innovation Officer, DirectorReveal Email/Phone
3
Chief StaffReveal Email/Phone
4
Chief Scientific OfficerReveal Email/Phone
5
Head PharmaceuticalsReveal Email/Phone
6
Senior Project ManagerReveal Email/Phone
7
ControllerReveal Email/Phone
8
Research AssistantReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$3.1M4018%$40MN/A
#2
$0.2M20%N/AN/A
#3
$1.3M17-15%N/AN/A
#4
$2.6M176%N/AN/A
#5
$12.9M835%N/AN/A
#6
$1.9M244%$89.5MN/A
#7
$2.8M186%N/AN/A
#8
$40.3M26021%N/AN/A
#9
$0.9M60%N/AN/A
#10
$0.6M4-20%N/AN/A
Add Company

What Is SaNOtize Research and Development Corp.?

SaNOtize has developed and patented (issued) a Nitric Oxide Releasing Solution platform technology to treat and prevent microbial infections, including drug resistant microbes. Target indications include treatment for strep throat, athlete's foot, infected wounds, diabetic foot ulcers, sinusitis, cold and flu and others. With antibiotic resistance increasing in the world, SaNOtize's platform technology can help fight resistance and bring a new innovating solution to fight infections.

keywords:N/A

N/A

Total Funding

26

Number of Employees

$2M

Revenue (est)

8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$8.3M26-13%$15.8M
#2
$2.6M26N/AN/A
#3
$3.7M260%N/A
#4
$3.5M264%N/A
#5
$3.1M268%N/A